Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier.
The mucosa represents the primary target site and thus the first barrier for most microbial pathogens. Nevertheless, nearly all present-day vaccines are applied by an invasive route, target the systemic immune system, and do not confer efficient mucosal protection. Currently, mucosal immunity can only be achieved by the delivery of antigens via the mucosal route. Therefore, multiple efforts are under way to develop mucosal vaccines and particularly live oral vaccines as these would confer considerable advantages. We have engineered the AIDA autotransporter system for the surface presentation and/or release of heterologous polypeptides. This study is focused on the development and evaluation of a tripartite live bacterial vector system for oral vaccination based on the AIDA autotransporter, heterologous virulence factor-derived (poly-)peptides, and the apathogenic Escherichia coli Nissle 1917 strain as a live carrier. Potentially with this system also attenuated Salmonella or Shigella strains might be employed as carriers. Model antigens included e.g. the p60 antigen of Listeria monocytogenes, the OspA/OspG antigens of B. burgdorferi, the LT-B subunit of E. coli, and Stx-B subunits of enterohemorrhaghic E. coli (EHEC), all representing crucial virulence factors of important bacterial pathogens. Exemplary oral immunization studies were conducted using different regimes in BALB/c mice with candidate vaccines expressing Stx B-subunits and OspA and OspG proteins. To monitor the induction of immune responses, specific antibody titers in serum as well as secreted mucosal antibodies of local and distal mucosal surfaces were determined. Antigen-specific mucosal as well as systemic antibodies could be induced; however, thus far the response turned out to be heterogeneous and appeared not to be sufficient to mediate protection.
Buddenborg
Christian
C
Institut für Infektiologie, Zentrum für Molekularbiologie der Entzündung, Westfälische Wilhelms-Universität Münster, Von-Esmarch-Str. 56, D-48149 Münster, Germany.
Daudel
Damini
D
Liebrecht
Shanti
S
Greune
Lilo
L
Humberg
Verena
V
Schmidt
M Alexander
MA
D018830:Adhesins, Escherichia coli / Q000276:immunology*; D000284:Administration, Oral; D000818:Animals; D004926:Escherichia coli / Q000276:immunology*; D004927:Escherichia coli Infections / Q000276:immunology* / Q000382:microbiology / Q000517:prevention & control; D022361:Escherichia coli Vaccines / Q000008:administration & dosage / Q000276:immunology*; D005822:Genetic Vectors; D006801:Humans; D018928:Immunity, Mucosal / Q000276:immunology*; D019936:Probiotics / Q000008:administration & dosage*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
C075559:AIDA-I protein, E coli; D018830:Adhesins, Escherichia coli; D022361:Escherichia coli Vaccines; D014613:Vaccines, Attenuated